Remdesivir’s price, RWD’s moment & a genomics breakup: a BioCentury Podcast

Gilead has done the biopharma industry a favor by giving remdesivir a Goldilocks price, according to BioCentury Washington Editor Steve Usdin. On the latest edition of the BioCentury This Week podcast, Usdin discusses remdesivir’s price, supply and future prospects as well as HHS’s deal to secure at least 90% of Gilead’s production of the antiviral for the next three months.

Usdin and colleagues also explore the critical role of real-world data during the pandemic, as well as WuXi NextCode’s decision to split up one of the world’s leading genomics platforms...